Alignment Healthcare ALHC
- Market cap
- $1.5B
- PE
- 53.8×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.3×
- EV/EBIT
- 19.8×
- Revenue, 12 months
- $4.9B
- +36% on a year ago
- Net margin
- 0.6%
- Free cash flow yield
- 5.3%
Alignment Healthcare trades at 53.8× trailing earnings. Revenue was $4.9B over the last twelve months, up 36% on a year earlier with a 1% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $465.4M+29% | $628.6M+43% | $681.3M+47% | $692.4M+52% | $701.2M+51% | $926.9M+48% | $1B+49% | $993.7M+44% | $1B+44% | $1.2B+33% | $1.3B+32% | $1.4B+37% | |
| SG&A | $83.7M+1% | $90.5M+29% | $87.9M+25% | $90.9M+9% | $102.1M+22% | $103.8M+15% | $103.8M+18% | $110M+21% | $125.8M+23% | $121.1M+17% | $131M+26% | $136.4M+24% |
| −$41.9M−20% | −$41.1M+27% | −$18.4M−22% | −$19.5M−34% | −$22.5M−46% | −$5.4M−87% | $22.7M | $7.7M | −$10.3M−54% | $15.5M | $42.1M+85% | −$3.8M | |
| Interest expense | $5.5M+14% | $5.4M+8% | $5.7M+8% | $6.9M+27% | $5.5M+0% | $4M−27% | $4M−31% | $4M−43% | $3.9M−28% | $4.1M+3% | $4.3M+8% | $4.3M+8% |
| Pre-tax income | −$47.3M−17% | −$46.6M+25% | −$24M−16% | −$26.4M−25% | −$31.1M−34% | −$9.3M−80% | $18.9M | $3.7M | −$14.2M−54% | $11.4M | $37.8M+100% | −$8.1M |
| −$24K | $0 | $22K+2100% | −$8K | $7K | $21K | $3.2M+14555% | $2K | −$3.2M | $25K+19% | $1.3M−61% | −$22K | |
| Net income | −$47.2M−17% | −$46.5M+25% | −$24M−16% | −$26.4M−25% | −$31.1M−34% | −$9.1M−80% | $15.7M | $3.7M | −$11M−65% | $11.4M | $36.6M+133% | −$8.1M |
| −$0.25 | −$0.25+25% | −$0.13−13% | −$0.14−26% | −$0.16−36% | −$0.05−80% | $0.07 | $0.02 | −$0.05−69% | $0.05 | $0.17+143% | −$0.04 | |
| 188.4M | 189M+3% | 190.9M+3% | 191.4M+2% | 191.9M+2% | 193.6M+2% | 209.5M+10% | 208.9M+9% | 201M+5% | 213.1M+10% | 215M+3% | 208.6M−0% |
EPS, diluted: 4 periods, Q4 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q2 FY21 and Q3 FY21: a loss quarter: its basic count, printed 3 months. 4 periods, Q4 FY21 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q2 FY22: a loss quarter: its basic count, share-days: the 6-month average less the 3-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Alignment Healthcare's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ALHCAlignment Healthcare | $1.5B | 53.8× | 76.9× | 0.3× | +36% | 0.6% | |
| PCRXPacira BioSciences | $1.5B | 104× | 65.7× | 1.9× | +6% | 2.0% | |
| PNTGPennant | $1.4B | 45.0× | 46.5× | 1.3× | +38% | 2.9% | |
| ANABAnaptysbio | $1.4B | 10.3× | 99.3× | n/m | n/m | n/m | |
| HLFHerbalife | $1.4B | 8.6× | 10.3× | 0.3× | +6% | 3.2% | |
| CNMDCONMED | $1.4B | 19.3× | 52.9× | 1.0× | +2% | 5.4% | |
| PAHCPhibro Animal Health | $1.6B | 15.9× | 21.5× | 1.0× | +17% | 6.6% | |
| EYENational Vision | $1.4B | 28.1× | 52.7× | 0.7× | +8% | 2.5% | |
| CDRECadre | $1.3B | 38.9× | 35.9× | 2.0× | +20% | 5.3% | |
| TRUPTrupanion | $1.3B | 58.0× | 58.8× | 0.9× | +12% | 1.5% | |
| ANIPANI Pharmaceuticals | $1.6B | 15.0× | 57.5× | 1.7× | +31% | 11.1% | |
| Peer median | $1.4B | 23.7× | 52.8× | 1.0× | +12% | 3.2% |
More on Alignment Healthcare
Each number over time
- PE ratio
- Price to sales ratio
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #3of 11Health insurers with the fastest revenue growth
- #5of 11Health insurers with the lowest price to sales ratio
- #8of 11Health insurers with the highest profit margins
- #9of 10Health insurers with the lowest EV/EBIT
Its groups
About
- Industry
- Medical - Healthcare Plans
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .